Managing hyperlipidemia: Current and future roles of HMG-CoA reductase inhibitors

American Journal of Health-System Pharmacy

Volumn 59, Issue 12, 2002, Pages 1173-1182

  Lopez, Larry M ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Antilipemic agents; Coronary disease; Hyperlipidemia

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; UNSTABLE ANGINA PECTORIS; ANIMAL; PHARMACIST; RISK FACTOR;

ANIMALS; ANTILIPEMIC AGENTS; CORONARY DISEASE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; PHARMACISTS; RISK FACTORS;

EID: 0037097814     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.12.1173     Document Type: Review

References (56)

1. Prevention of coronary heart disea3e with pravastatin in men with hypercholesterolemia
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
4. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
5. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
6. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial
7. Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction
8. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
9. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
10. Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS)
11. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])
12. The evolving role of statins in the management of atherosclerosis
13. Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation
14. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
15. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
16. Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data
17. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease
18. The lipid assessment project (L-TAP)
19. Treatment patterns and distribution of lowdensity lipoprotein cholesterol levels in treatment-eligible United States adults
20. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines
21. Use of lipidlowering medications at discharge in patients with acute myocardial infarction. Data from the National Registry of Myocardial Infarction 3
22. When to start cholesterol-lowering therapy in patients with coronary heart disease
23. Potential influence of timing of lowdensity lipoprotein cholesterol evaluation in patients with acute coronary syndrome
24. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
25. Reduced coronary events in simvastatintreated patients with coronary heart disease and diabetes or impaired glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival Study
26. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease
27. Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial
28. Management of dyslipidemia in adults with diabetes
29. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines
30. Guide to preventive cardiology for women
31. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
32. Effects of estrogen replacement on the progression of coronaryartery atherosclerosis
33. Hormone replacement therapy and cardiovascular disease. A statement for healthcare professionals from the American Heart Association
34. Serum lipids and incidence of coronary heart disease: Findings from the Systolic Hypertension in the Elderly Program (SHEP)
35. ACC/AHA-ASIM guidelines for the management of patients with chronic stable angina: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina)
36. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
37. Treating to meet NCEP recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease
38. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended lowdensity-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin, and simvastatin
39. Comparing treatment success with statins: Results from the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS)
40. Rationale and design of the cardiac hospitalization atherosclerosis management program at the University of California Los Angeles
41. Withdrawal of statins increases event rates in patients with acute coronary syndromes
42. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study
43. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events
44. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS)
45. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
46. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
47. Pravastatin therapy and risk of stroke
48. Reduction of stroke events with pravastatin. The Prospective Pravastatin Pooling Project (PPP)
49. Reductase inhibitor monotherapy and stroke prevention
50. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized controlled trials
51. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: An overview of randomized trials
52. Current perspectives on statins
53. Rhabdomyolysis and HMG-CoA reductase inhibitors
54. Pharmaceutical care services and results in Project ImPACT. Hyperlipidemia
55. Post-hospitalization management of high-risk coronary patients
56. Strategies for implementing lipidlowering therapy: Pharmacy-based approach